Sophie Roider‐Schur

Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial

Rupert Bartsch, Anna S. Berghoff, Julia Furtner et al. · Nature Medicine · 2022 · 392 citations · Full text

Medicine, Oncology, Pharmacology +17

Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases

Rupert Bartsch, Anna S. Berghoff, Julia Furtner et al. · Neuro-Oncology · 2024 · 57 citations · Full text

Medicine, Oncology, Pharmacology +17

280P Intracranial activity of trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients with active brain metastases: Results from the first stage of the phase II TUXEDO-1 trial

Rupert Bartsch, Anna S. Berghoff, Julia Furtner et al. · Annals of Oncology · 2021 · 23 citations

Medicine, Oncology, Breast Oncology +16

Ramucirumab plus paclitaxel or FOLFIRI in platinum-refractory advanced or metastatic gastric or gastroesophageal junction adenocarcinoma—experience at two centres

Ursula Vogl, Laurenz Vormittag, Thomas Winkler et al. · Journal of Gastrointestinal Oncology · 2020 · 14 citations · Full text

Medicine, Oncology, Pharmacology +16

[Austrian guideline for palliative sedation therapy (long version) : Results of a Delphi process of the Austrian Palliative Society (OPG)].

Dietmar Weixler, Sophie Roider‐Schur, Rudolf Likar et al. · PubMed · 2017 · 12 citations

Medicine, Internal Medicine, End-of-life Care +15